Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternating Ixazomib and Lenalidomide Maintenance After Autologous Transplant in Multiple Myeloma
NCT02619682Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Dec 2015
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ixazomib, lenalidomide in multiple myeloma (MM), sponsored by Fred Hutchinson Cancer Center. Started Dec 2015; status: completed.
02
Drugs
ixazomiblenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02619682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02619682.